Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model

Prostate

Volumn 70, Issue 13, 2010, Pages 1461-1470

  Källberg, Eva ^a   Wikström, Pernilla ^b   Bergh, Anders ^b   Ivars, Fredrik ^a   Leanderson, Tomas ^a  

^a LUND UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

IDO; Immunology; TRAMP

Indexed keywords

CD31 ANTIGEN; CD45 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CELL COUNT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SERUM; STROMA; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; BLOOD; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LYMPH NODES; MALE; MICE; PROSTATIC NEOPLASMS; TRYPTOPHAN;

EID: 77956621031     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21181     Document Type: Article

References (19)

1. Abate-Shen C, Shen MM,. Molecular genetics of prostate cancer. Genes Dev 2000; 14 (19): 2410 -2434.
2. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD,. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450 (7171): 903 -907.
3. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev 2009; 9 (3): 162 -174.
4. Munn DH, Mellor AL,. IDO and tolerance to tumors. Trends Mol Med 2004; 10 (1): 15 -18.
5. Mellor AL, Munn DH,. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev 2004; 4 (10): 762 -774.
6. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH,. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117 (9): 2570 -2582.
7. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA III, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL,. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 2008; 105 (44): 17073 -17078.
8. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM,. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92 (8): 3439 -3443.
9. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM,. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56 (18): 4096 -4102.
10. Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, Sanda MG,. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 1999; 54 (6): 1112 -1119.
11. Wikstrom P, Lindahl C, Bergh A,. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 2005; 62 (2): 148 -164.
12. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH,. Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171 (4): 1652 -1655.
13. Kallberg E, Leanderson T,. A subset of dendritic cells express joining chain (J-chain) protein. Immunology 2008; 123 (4): 590 -599.
14. Laich A, Neurauter G, Widner B, Fuchs D,. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002; 48 (3): 579 -581.
15. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP,. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60 (9): 2444 -2448.
16. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M,. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35 (1): 66 -75.
17. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL,. GCN2 kinase in T cells mediates proliferative arrest and energy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22 (5): 633 -642.
18. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ,. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9 (10): 1269 -1274.
19. Feder-Mengus C, Wyler S, Hudolin T, Ruszat R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A, Gasser TC, Sulser T, Heberer M, Spagnoli GC, Provenzano M,. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer 2008; 44 (15): 2266 -2275.